Summary of Federal Project Grant Award

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $231,000 Project Grant to the Regents of the University of Michigan on April 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This R56 award supports research on remote loading of melanocortin (MC) and glucagon-like peptide-1 (GLP-1) peptides in polymers for obesity treatment. The research team will further develop and optimize a water-based remote encapsulation method for loading GLP-1 peptides into poly(lactic-co-glycolic acid) (PLGA) microspheres, while advancing understanding of the underlying mechanisms of rapid and spontaneous remote peptide loading at physiological temperature. The project extends through March 31, 2027, and is performed at the University of Michigan's Ann Arbor campus.

The scientific deliverables address gaps in current obesity therapeutics by investigating novel peptide combinations and delivery mechanisms designed to improve therapeutic potency, reduce adverse effects, and enable cost-effective encapsulation approaches. Prior work has yielded melanocortin peptides with four-fold increased potency relative to approved setmelanotide, as well as evidence that melanocortin peptides enhance GLP-1 dose sensitivity while reducing nausea and central nervous system activity. The encapsulation methodology aims to overcome current limitations in peptide-based obesity treatments, including variable efficacy, side effects, and administration burden.